Cardiff Oncology Stock (NASDAQ:CRDF)
Previous Close
$2.58
52W Range
$1.12 - $6.42
50D Avg
$2.83
200D Avg
$3.08
Market Cap
$133.97M
Avg Vol (3M)
$689.53K
Beta
1.93
Div Yield
-
CRDF Company Profile
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
CRDF Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GRCL | Gracell Biotechnologies Inc. |
| CUE | Cue Biopharma, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| MREO | Mereo BioPharma Group plc |
| NLSP | NLS Pharmaceutics AG |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PDSB | PDS Biotechnology Corporation |
| RNAZ | TransCode Therapeutics, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| SLS | SELLAS Life Sciences Group, Inc. |
| LTRN | Lantern Pharma Inc. |
| EFTR | eFFECTOR Therapeutics, Inc. |
| KOD | Kodiak Sciences Inc. |
| EYEN | Eyenovia, Inc. |
| INAB | IN8bio, Inc. |
| AUTL | Autolus Therapeutics plc |
| CGTX | Cognition Therapeutics, Inc. |
| LYRA | Lyra Therapeutics, Inc. |